Peptide · Fact sheet

Sermorelin

Also known as Geref · sermorelin acetate

Sermorelin is not currently available as an FDA-approved marketed drug product. The former Geref product was discontinued, and that history does not make current compounded versions FDA approved.

DiscontinuedLimited or unclear evidence

What is Sermorelin?

Sermorelin is a manufactured fragment of growth hormone-releasing hormone that can stimulate growth-hormone release from the pituitary gland.

A former branded product, Geref, had approved diagnostic and pediatric uses before being discontinued from marketing.

Benefits & claims

It is frequently promoted in anti-aging and body-composition contexts.

Those marketing claims need to be separated from the discontinued product's regulatory history and the limited evidence for today's promoted uses.

What the evidence supports

  • Sermorelin can stimulate the growth-hormone pathway, which explains its historical diagnostic role.
  • A biological effect does not by itself prove meaningful anti-aging, weight, or performance benefits.
Research areas
  • Growth hormone secretion testing
  • Growth hormone deficiency in historical contexts
  • Growth hormone pathway effects
  • Various growth-hormone-pathway outcomes outside a currently marketed FDA-approved product

Dosage & frequency

No established human regimen

Geref is a discontinued FDA-approved sermorelin product. That historical approval does not establish a current compounded anti-aging schedule.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • Historical diagnostic or pediatric treatment use and present-day off-label preparations are different contexts.

Interactions & precautions

  • Historical Geref evidence does not establish interactions for current off-label adult hormone combinations.

What is still unresolved

  • A validated adult anti-aging regimen and long-term clinical benefits remain unestablished.

Side effects & risks

  • Current compounded products do not undergo FDA premarket review for safety, effectiveness, or quality.
  • Potential effects of stimulating the growth-hormone pathway can matter for glucose control, fluid retention, and other health conditions.
  • Product purity, sterility, strength, and labeling are separate concerns for unapproved products.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Limited or unclear evidence

Human physiology and the former product are documented, but high-quality evidence for many current wellness, anti-aging, or body-composition claims is limited or unclear.

Studies

Sermorelin review

Peer-reviewed review of sermorelin in diagnostic and therapeutic contexts.

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 3 sourced accounts by reported effect.

Energy: reported experiences

Negative account · personal report

Feeling tired but wired

A commenter using sermorelin with hexarelin described bodily heaviness, anxiety, an alert mind and difficulty sleeping, with stimulation again on a later exposure.

Reported use in this account

Product
Product labeled sermorelin/hexarelin combination
Amount
Not specified clearly
Frequency
Not specified clearly
Route
Injection; specific route not stated
Duration
About two weeks

Other exposures described: Hexarelin

This combined exposure cannot identify sermorelin as the cause; contents and health context were unverified.

Read the original account

Approval status

The FDA-approved Geref product is discontinued from marketing. Current compounded sermorelin products are not FDA-approved drug products, and discontinuation history should be checked in Drugs@FDA.

Previously approved product discontinued

Geref, a sermorelin acetate product, was discontinued. A discontinued product is not the same as a currently marketed FDA-approved option for wellness or anti-aging use.

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Long-term safety for commonly promoted off-label wellness goals
  • Reliable benefits for anti-aging or body-composition claims
  • Consistency and quality of products outside an approved drug application

Summary

Sermorelin's past approval does not confer approval on products sold today. Current claims should be evaluated against current product status and human evidence.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. fdaFederal Register: Geref discontinuation determination

    FDA determination that the Geref discontinuation was not for safety or effectiveness reasons.

  2. fdaFDA review noting Geref discontinuation

    FDA clinical pharmacology review referencing the discontinued Geref product.

  3. pubmedSermorelin review

    Peer-reviewed review of sermorelin in diagnostic and therapeutic contexts.

  4. pubmedSermorelin in children with growth-hormone deficiency

    Clinical literature on historical sermorelin use in pediatric growth-hormone deficiency.

How we assess sources · Suggest a correction